Regulatory
35 articles in the Regulatory category
Health Canada and Research Peptides: What the 2024 to 2026 Enforcement Record Actually Says
Five public advisories, read from the primary documents: what Health Canada seized from two named Canadian sellers, the statutory test that triggered it, why "research use only" is not an exemption, and the lot-level documentation checks that survive this environment.
32 min read
Eli Lilly Sets FDA Filing Date for Next Weight-Loss Drug, Pressuring Novo Nordisk
Eli Lilly has officially announced the timing of its FDA filing for its next weight-loss drug, a move that intensifies competitive pressure on Novo Nordisk. The announcement clarifies the regulatory timeline for the highly anticipated treatment.
5 min read
Eli Lilly Sets Retatrutide FDA Filing Date; Stock Target Questioned
Eli Lilly has locked in a U.S. Food and Drug Administration (FDA) filing date for its investigational obesity drug retatrutide, according to a recent report. The news has sparked analyst discussion about whether the company's stock could reach $1,750 by 2027. The filing date marks a key regulatory milestone for the potential blockbuster therapy.
5 min read
FDA Peptide Vote Explained: Why These Drugs Await Approval
A recent FDA advisory vote has left many peptide-based drugs unapproved, raising questions about the regulatory path forward. This article explains the vote's context, the reasons behind the delay, and what it means for developers and patients.
4 min readBachem Holding AG Class B Revenue Breakdown on SIX:BANB
Bachem Holding AG, listed on the SIX Swiss Exchange under ticker BANB for its Class B shares, has published a revenue breakdown. The report, dated August 1, 2026, details the company's financial performance. This analysis provides a clear view of Bachem's revenue streams.
6 min readBachem Stock Under Pressure as Capex Rises and Margins Tighten
Bachem (SWX:BANB) faces margin strain as capital expenditures surge, according to a recent analysis. The report highlights growing financial pressure on the Swiss peptide manufacturer despite its market position. Investors are watching how the company balances expansion with profitability.
6 min readThyroid Meds Recalled Nationwide; GLP-1 Hair Loss Risks and PMOS Data
A nationwide recall of thyroid medications has been announced, affecting multiple brands. New research highlights which GLP-1 drug may carry the highest risk for hair loss. Additionally, prevalence data on postmenopausal ovarian syndrome (PMOS) has been published, offering fresh insights into this condition.
5 min readFDA Urged to Reject Untested Peptides in Compounded Medications
The Information Technology and Innovation Foundation (ITIF) published a blog on July 22, 2026, arguing that the FDA should not allow untested peptides to be added into patients' medications. The piece warns that adding unapproved peptides to compounded drugs poses serious safety risks without proven benefits, and calls for stronger regulatory oversight to protect public health.
5 min read
Cenna Biosciences Gets FDA Clearance for Phase 1 Trial of Alzheimer's Peptide 8M2D
Cenna Biosciences has received FDA clearance to begin a Phase 1a/1b clinical trial for 8M2D, a first-in-class peptide designed to stop amyloid production in Alzheimer's disease. The announcement was made on June 17, 2026, marking a regulatory milestone for the experimental therapy.
1 min read
Cenna Biosciences Gets FDA Nod for Alzheimer's Peptide Trial
Cenna Biosciences has received FDA clearance to begin a Phase 1a/1b clinical trial of 8M2D, a first-in-class peptide designed to stop amyloid production in Alzheimer's disease. The regulatory green light marks a key step toward testing the novel therapeutic in humans.
2 min read
FDA Warns Telehealth Companies Over Compounded GLP-1 Drugs
The U.S. Food and Drug Administration has issued warnings to telehealth companies regarding the compounding of GLP-1 receptor agonists. The agency's actions target firms that may be producing or distributing unapproved versions of these popular diabetes and weight loss medications. The warnings underscore ongoing regulatory scrutiny of compounded semaglutide and tirzepatide products.
3 min read
FDA Intensifies Enforcement Against GLP-1 Drug Compounders
The U.S. Food and Drug Administration has renewed its enforcement actions against compounding pharmacies that produce unapproved versions of GLP-1 receptor agonists. This regulatory move targets compounders making copies of drugs like Novo Nordisk's Ozempic and Wegovy, which are currently in high demand and short supply.
2 min read
HIMS Stock Tops $30 Ahead of FDA Peptide Review, Analysts Watch
HIMS stock broke above $30 ahead of an upcoming FDA peptide review. Analysts are eyeing this as the next growth catalyst for the company. The stock move comes as the regulatory review approaches.
1 min read
Cagrilintide-Semaglutide May Aid Type 2 Diabetes Glycemic Control
A combination of cagrilintide and semaglutide could improve glycemic control in patients with type 2 diabetes who are already using basal insulin, according to a report from Docwire News. The finding suggests a potential new treatment option for managing blood sugar levels in this patient population.
1 min read
Peptide Interest Surges But FDA 2026 Docket Smaller Than Reported
Interest in peptide therapeutics is growing rapidly, but the FDA's actual regulatory docket for 2026 is far smaller than what has been reported. The Charlotte Observer notes the discrepancy between public perception and the agency's official agenda.
2 min read
Poll Investigates Reasons Behind Rising Weight-Loss Drug Errors
A new poll from WOAI explores what is driving an increase in mistakes involving weight-loss medications. The survey aims to identify the primary factors behind the spike in errors. The findings are based on public responses collected by the news outlet.
2 min readIs Tirzepatide Better Than Semaglutide for Weight Loss? Comparison
A comparison examines if Tirzepatide outperforms Semaglutide for weight loss. The two drugs are directly contrasted on this measure. This regulatory news covers the key question of superiority.
2 min readFDA Approves Foundayo for Weight Loss in Orforglipron News
The FDA has approved Foundayo for weight loss, according to Orforglipron news from GoodRx. This regulatory decision highlights developments in weight management options. The approval positions Foundayo as a new tool for addressing obesity.
2 min readFDA Eyes Lifting Restrictions on Cosmetic Peptides
The FDA shows signs of reevaluating restrictions on cosmetic peptides like GHK-Cu and SNAP-8, which face limits in compounding pharmacies despite use in low-concentration skincare products. These compounds offer benefits in skin rejuvenation and wound healing but remain on restricted lists under Section 503A. Recent agency feedback requests hint at possible changes to improve access.
3 min readFDA Shake-Up and Growing Frustration with Prior Auth Reform
A shake-up is taking place at the FDA. Frustration continues to grow over prior auth reform. These regulatory matters affect pharmaceutical operations and draw attention from industry participants. The combination of the FDA shake-up and prior auth reform issues forms a central focus in current discussions. Observers note both elements as active concerns.
1 min readSemaglutide Reduces Obesity in Treatment-Resistant Young Adults
Semaglutide has shown significant effects in lowering obesity levels among young adults who do not respond to standard treatments. This development highlights a potential option for a challenging patient group. The findings point to semaglutide's role in addressing persistent obesity cases.
1 min readDaily Orforglipron Preserves Weight Loss After Semaglutide or Tirzepatide
Once-daily orforglipron helps preserve weight loss after semaglutide or tirzepatide. The medication supports maintenance of weight reduced during prior use of these treatments. Its once-a-day schedule aids in sustaining results from semaglutide or tirzepatide therapy.
2 min readRoche Secures CE Mark for Second Eli Lilly Alzheimer’s Test
Roche has obtained a European CE mark for its second Alzheimer’s test developed with Eli Lilly. The diagnostic can confirm the disease or rule it out. This approval enables use across Europe for better patient assessment.
2 min readFDA Takes Aim at GLP-1 Compounders in Pharmacies
The FDA has directed its regulatory attention toward compounders of GLP-1 drugs. Pharmacies engaged in producing these medications face agency focus as of May 13, 2026. This development highlights oversight on GLP-1 compounding activities.
2 min readFDA Proposes Excluding GLP-1s from 503B Bulk List
The U.S. Food and Drug Administration proposes to exclude GLP-1s from the 503B bulk list. This proposal focuses on removing GLP-1s from that specific list. The action signals a change in how GLP-1s are handled under 503B rules.
2 min readFDA Moves to Restrict Bulk Compounding of Novo, Lilly Weight-Loss Drugs
The FDA plans to limit bulk compounding of weight-loss drugs from Novo and Lilly. This action targets practices involving these popular medications. Regulators aim to control how such drugs are produced in large quantities by compounding pharmacies.
2 min readFDA Proposes Ban on Bulk Compounding of Semaglutide and Tirzepatide
The U.S. Food and Drug Administration has proposed a ban on bulk compounding of semaglutide and tirzepatide. This regulatory proposal names semaglutide and tirzepatide as the drugs subject to the ban. The action focuses on prohibiting bulk compounding for these two medications.
1 min read
GLP-1 Agonists Linked to Better Breast Cancer Survival Signals
A large retrospective study in JAMA Network Open links GLP-1 receptor agonist use to improved survival and recurrence outcomes in women with breast cancer, obesity, or type 2 diabetes. The analysis from 841,831 patients shows strong hazard ratios, such as 0.35 for mortality in obesity cases. Observational data raises questions about causality and confounding.
3 min read
Oral Semaglutide Delivers 21.6% Weight Loss in Early Responders, 77.3% Mobility Gains
In the OASIS 4 trial, oral semaglutide 25 mg led to 21.6% weight loss among early responders, who made up 28.8% of participants with at least 10% loss by week 16. Those not meeting that mark, nearly three-quarters, still achieved 11.5% weight loss by week 64. Participants with poor baseline physical function saw 77.3% achieve meaningful improvements versus 42.9% on placebo.
3 min readFDA Acts to End Large-Scale GLP-1 Drug Compounding
The FDA is moving to stop large-scale compounding of GLP-1 drugs, as detailed in a JD Supra article. This regulatory step targets production practices for these medications.
2 min readFDA Approves Orforglipron, Widens Obesity and Oral GLP-1 Access
The FDA has approved Orforglipron, broadening access to obesity treatments and oral GLP-1 therapies. Pharmacy Times covered this regulatory milestone on May 4, 2026. The decision provides more options for patients managing obesity through oral medications.
2 min readFDA Blocks Select Compounded GLP-1s Affecting Online Prescriptions
The FDA is acting to prevent certain compounded GLP-1 medications. This regulatory step influences online prescription services. A Forbes article outlines the details and consequences for digital prescribing.
2 min readFDA Considers Lifting Restrictions on Numerous Compounded Peptides
The FDA plans to review easing restrictions on many compounded peptides, as noted by Foley & Lardner LLP.It falls under the regulatory category.
2 min readGala Health GLP-1 Review 2026: Verify Pricing, FDA, Refunds
A 2026 review of Gala Health's GLP-1 program notes changes in compounded GLP-1 access. It recommends checking pricing, FDA status, and refund terms before enrollment.
2 min readExercise Stays Vital with GLP-1 Obesity Treatments
Exercise continues to hold importance when paired with GLP-1 obesity treatments, as noted in a News-Medical report.This falls in the regulatory category and stresses physical activity's role.
2 min readOther categories